BridgeMD
New treatment option for Screening for Colon Cancer
Official title Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection
ClinicalTrials.gov ID: NCT06703632
What this study is testing
- What it's testing
- The objective of this low-risk interventional study is to evaluate whether the PreveCol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas when used prospectively in the screening population with a previous positive FOBT result, which could include any of the following: both sexes, age 50-69 years, asympthomatic volunteers. The main aims to be answered are: Values of efficacy, efficiency, impact and safety of PreveCol.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 69. Healthy volunteers may be eligible.
You may be able to join if
- Participants ages from 50 to 69 years (both included) at the time of informed consent signed.
- Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before...
- Participants with a positive result of FIT/FOBT analysis referred to the gastroenterology department who are eligible to undertake colonoscopy as a...
- Participants asymptomatic, average risk for CRC. Average risk is defined as those individuals who are age 50 or over with no history of adenoma...
You likely can't join if
- Participants who have developed any another type of cancer in the 5 years prior to their participation in the study.
- Participants who have previously received chemotherapy or radiotherapy (5 years).
- Participants previously or currently diagnosed with Familiar Adenomatous Polyposis or Lynch Syndrome or Inflammatory Bowel Disease.
- Inadequate intestinal preparation for colonoscopy with BBPS score ≤1 in any colon section, excluding diagnostic of CRC.
- Participants who have undergone polypectomy in the previous 5 years.
- Hemolysis of blood sample or absence of blood sample.
See the full eligibility criteria
- Participants ages from 50 to 69 years (both included) at the time of informed consent signed.
- Participants should sign an informed consent. They must understand the nature, significance, implications, and risks of the clinical study before signing the informed consent form.
- Participants with a positive result of FIT/FOBT analysis referred to the gastroenterology department who are eligible to undertake colonoscopy as a regular procedure of the colorectal cancer screening programme.
- Participants asymptomatic, average risk for CRC. Average risk is defined as those individuals who are age 50 or over with no history of adenoma, colorectal cancer, or inflammatory bowel disease, and with no family...
- Participants who have developed any another type of cancer in the 5 years prior to their participation in the study.
- Participants who have previously received chemotherapy or radiotherapy (5 years).
- Participants previously or currently diagnosed with Familiar Adenomatous Polyposis or Lynch Syndrome or Inflammatory Bowel Disease.
- Inadequate intestinal preparation for colonoscopy with BBPS score ≤1 in any colon section, excluding diagnostic of CRC.
- Participants who have undergone polypectomy in the previous 5 years.
- Hemolysis of blood sample or absence of blood sample.
- Participants who are arrested at judicial or official request
- Participants who are in a dependent personal or non-medical relationship with the Sponsor or the investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Lisbon, Lisbon District, Portugal
- Madrid, Madrid, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 69 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Lisbon, Lisbon District, Portugal; Madrid, Madrid, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.